https://www.prnewswire.com/news-releases/gracell-biotechnologies-announces-up-to-150-million-private-placement-financing-joined-by-a-syndicate-of-premier-healthcare-investors-301894490.html
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a...
/PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", Nasdaq: GRCL), a global clinical-stage biopharmaceutical company dedicated to...
https://www.prnewswire.com/news-releases/gracell-biotechnologies-to-participate-in-four-upcoming-investor-conferences-301613526.html
Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences
/PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and...
to participatein fourbiotechnologiesupcominginvestor
https://www.prnewswire.com/news-releases/gracell-biotechnologies-announces-fda-clearance-of-the-ind-application-for-phase-1b2-clinical-trial-of-fastcar-t-gc012f-for-the-treatment-of-relapsedrefractory-multiple-myeloma-301738212.html
Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical...
/PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to...
https://health.economictimes.indiatimes.com/news/pharma/pharma-industry/astrazeneca-to-buy-chinas-gracell-biotechnologies-in-1-2-bln-deal/106292062
AstraZeneca to buy China's Gracell Biotechnologies in $1.2 bln deal, ETHealthworld
The cash deal, which adds several experimental therapies to AstraZeneca's portfolio, values Gracell at $2 per ordinary share, or $10 per ADS of Gracell, plus a...
https://www.prnewswire.com/news-releases/gracell-biotechnologies-to-present-clinical-data-on-bcmacd19-dual-targeting-fastcar-t-gc012f-in-rrmm-and-b-nhl-and-donor-derived-car-t-gc007g-in-b-all-at-eha2023-congress-301822827.html
Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in...
/PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to...
https://www.prnewswire.com/news-releases/gracell-biotechnologies-appoints-veteran-biopharma-executive-dr-samuel-zhang-as-chief-business-officer-301588674.html
Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business...
/PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to...
https://www.gracellbio.com/
Gracell | Pioneering Next Generation CAR-T Therapies
Gracell | Pioneering Next Generation CAR-T Therapies
next generationpioneeringcartherapies
https://www.prnewswire.com/news-releases/gracell-biotechnologies-to-report-second-quarter-2022-financial-on-monday-august-15-2022-301597765.html
Gracell Biotechnologies to Report Second Quarter 2022 Financial on Monday, August 15, 2022
/PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly...
to reportsecond quarter
https://www.benzinga.com/news/23/12/36381855/gracell-biotechnologies-stratasys-hollysys-automation-technologies-and-other-big-stocks-moving-highe
Gracell Biotechnologies, Stratasys, Hollysys Automation Technologies And Other Big Stocks Moving...
Dec 26, 2023 - U.S. stock futures were higher this morning, with the Dow Jones futures gaining more than 40 points on Tuesday.
automation technologiesand otherbiotechnologiesstratasyshollysys
https://www.prnewswire.com/news-releases/gracell-biotechnologies-to-present-first-clinical-data-of-fastcar-t-gc012f-for-newly-diagnosed-multiple-myeloma-at-64th-american-society-of-hematology-annual-meeting--exposition-301667106.html
Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed...
/PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to...
https://www.prnewswire.com/news-releases/gracell-biotechnologies-doses-first-patient-in-phase-2-portion-of-registrational-phase-12-clinical-trial-evaluating-gc007g-for-treatment-of-b-cell-acute-lymphoblastic-leukemia-301650524.html
Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical...
/PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to...